Predicting the cumulative risk of false-positive mammograms.

Clinical practice. Mammographic screening for breast cancer. N Engl J Med (2003) 6.01

Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med (2011) 3.83

Long-term psychosocial consequences of false-positive screening mammography. Ann Fam Med (2013) 3.24

Variability in interpretive performance at screening mammography and radiologists' characteristics associated with accuracy. Radiology (2009) 2.88

Screening mammograms by community radiologists: variability in false-positive rates. J Natl Cancer Inst (2002) 2.71

Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med (2009) 1.94

Modelling the cumulative risk of a false-positive screening test. Stat Methods Med Res (2010) 1.87

Consequences of false-positive screening mammograms. JAMA Intern Med (2014) 1.81

A semiparametric censoring bias model for estimating the cumulative risk of a false-positive screening test under dependent censoring. Biometrics (2013) 1.52

Interventions to improve follow-up of abnormal findings in cancer screening. Cancer (2004) 1.41

Cumulative false positive recall rate and association with participant related factors in a population based breast cancer screening programme. J Epidemiol Community Health (2006) 1.23

Development of a clinical decision model for thyroid nodules. BMC Surg (2009) 1.21

Cost of breast-related care in the year following false positive screening mammograms. Med Care (2010) 1.19

Development of a Bayesian classifier for breast cancer risk stratification: a feasibility study. Eplasty (2010) 1.14

Initiation of benzodiazepines in the elderly after hospitalization. J Gen Intern Med (2007) 1.05

Effect of protocol-related variables and women's characteristics on the cumulative false-positive risk in breast cancer screening. Ann Oncol (2011) 1.00

Estimating the cumulative risk of false positive cancer screenings. BMC Med Res Methodol (2003) 0.98

Examining accuracy of screening mammography using an event order model. Stat Med (2006) 0.92

Effectiveness of early detection on breast cancer mortality reduction in Catalonia (Spain). BMC Cancer (2009) 0.89

A model of the influence of false-positive mammography screening results on subsequent screening. Health Psychol Rev (2010) 0.89

Prediction of higher mortality reduction for the UK Breast Screening Frequency Trial: a model-based approach on screening intervals. Br J Cancer (2011) 0.85

Evidence based case report: Advice about mammography for a young woman with a family history of breast cancer. BMJ (2001) 0.85

Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect. Breast Cancer Res (2005) 0.84

Comparison of cumulative false-positive risk of screening mammography in the United States and Denmark. Cancer Epidemiol (2015) 0.84

False-positive results in the randomized controlled trial of mammographic screening from age 40 ("Age" trial). Cancer Epidemiol Biomarkers Prev (2010) 0.83

A molecular computational model improves the preoperative diagnosis of thyroid nodules. BMC Cancer (2012) 0.81

Development and validation of queries using structured query language (SQL) to determine the utilization of comparison imaging in radiology reports stored on PACS. J Digit Imaging (2006) 0.80

Statistical Methods for Estimating the Cumulative Risk of Screening Mammography Outcomes. Cancer Epidemiol Biomarkers Prev (2015) 0.79

Another look at Emergency Department HIV screening in practice: no need to revise expectations. AIDS Res Ther (2010) 0.79

Epidemiological aspects of cancer screening in Germany. J Cancer Res Clin Oncol (2003) 0.79

Imaging-based screening: maximizing benefits and minimizing harms. Clin Imaging (2015) 0.79

Informed consent for mammography screening: modelling the risks and benefits for American women. Health Expect (2005) 0.79

False positives in breast cancer screening with one-view breast tomosynthesis: An analysis of findings leading to recall, work-up and biopsy rates in the Malmö Breast Tomosynthesis Screening Trial. Eur Radiol (2016) 0.78

Doctor, what does my positive test mean? From Bayesian textbook tasks to personalized risk communication. Front Psychol (2015) 0.78

Breast cancer screening: an evidence-based update. Med Clin North Am (2015) 0.78

Joint modeling of sensitivity and specificity. Stat Med (2008) 0.78

Towards personalized screening: Cumulative risk of breast cancer screening outcomes in women with and without a first-degree relative with a history of breast cancer. Int J Cancer (2015) 0.78

Non-invasive optical estimate of tissue composition to differentiate malignant from benign breast lesions: A pilot study. Sci Rep (2017) 0.77

Racial differences in false-positive mammogram rates: results from the ACRIN Digital Mammographic Imaging Screening Trial (DMIST). Med Care (2015) 0.77

Cumulative risk of false positive test in relation to breast symptoms in mammography screening: a historical prospective cohort study. Breast Cancer Res Treat (2016) 0.77

Is the false-positive rate in mammography in North America too high? Br J Radiol (2016) 0.76

Risk of breast cancer after false-positive results in mammographic screening. Cancer Med (2016) 0.75

Psychological Outcomes After a False Positive Mammogram: Preliminary Evidence for Ethnic Differences Across Time. J Racial Ethn Health Disparities (2016) 0.75

Association between Breast Parenchymal Complexity and False-Positive Recall From Digital Mammography Versus Breast Tomosynthesis: Preliminary Investigation in the ACRIN PA 4006 Trial. Acad Radiol (2016) 0.75

False-positive mammography and depressed mood in a screening population: findings from the New Hampshire Mammography Network. J Public Health (Oxf) (2009) 0.75

Mediators of repeat mammography in two tailored interventions for Iranian women. BMC Public Health (2016) 0.75

Broadband optical mammography instrument for depth-resolved imaging and local dynamic measurements. Rev Sci Instrum (2016) 0.75

Breast cancer risk is increased in the years following false-positive breast cancer screening. Eur J Cancer Prev (2016) 0.75

Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med (1998) 12.20

Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol (1997) 10.61

Visualizing an olfactory sensory map. Cell (1996) 8.79

Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell (1991) 7.40

Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A (1989) 6.32

A novel receptor-mediated nuclear protein import pathway. Cell (1996) 6.04

Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A (1987) 5.68

Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science (1995) 5.65

Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem (1992) 5.60

The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins. Cell (1997) 5.28

Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. EMBO J (1992) 5.23

The rational clinical examination. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How? JAMA (1999) 4.80

Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol (1988) 4.55

The effects of blinding on the quality of peer review. A randomized trial. JAMA (1990) 4.39

Conduction at domain walls in oxide multiferroics. Nat Mater (2009) 4.18

Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med (1990) 3.93

Pre-mRNA splicing imprints mRNA in the nucleus with a novel RNA-binding protein that persists in the cytoplasm. Mol Cell (2000) 3.86

Two-headed binding of a processive myosin to F-actin. Nature (2000) 3.73

A bicistronic Epstein-Barr virus mRNA encodes two nuclear proteins in latently infected, growth-transformed lymphocytes. J Virol (1987) 3.58

Manuscript quality before and after peer review and editing at Annals of Internal Medicine. Ann Intern Med (1994) 3.42

Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem (2000) 3.37

Helping patients decide about back surgery: a randomized trial of an interactive video program. Spine (Phila Pa 1976) (2001) 3.32

The breast is close to the heart. Ann Intern Med (1992) 3.29

Problems of comorbidity in mortality after prostatectomy. JAMA (1992) 3.27

Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J Virol (1991) 3.24

Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J Virol (1990) 3.24

The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem (1992) 3.13

Issues in the epidemiology and population-based screening of primary angle-closure glaucoma. Surv Ophthalmol (1992) 3.00

Has medicine outgrown physical diagnosis? Ann Intern Med (1992) 2.90

Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years. J Natl Cancer Inst (1998) 2.86

Tissue structure, nuclear organization, and gene expression in normal and malignant breast. Cancer Res (1999) 2.84

Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol (2006) 2.79

Effects of peer review and editing on the readability of articles published in Annals of Internal Medicine. JAMA (1994) 2.73

The characteristics of peer reviewers who produce good-quality reviews. J Gen Intern Med (1993) 2.68

Epstein-Barr virus infection and replication in a human epithelial cell system. Nature (1992) 2.62

Definitive identification of a member of the Epstein-Barr virus nuclear protein 3 family. Proc Natl Acad Sci U S A (1986) 2.62

Population genetic implications from sequence variation in four Y chromosome genes. Proc Natl Acad Sci U S A (2000) 2.62

Leukocytes navigate by compass: roles of PI3Kgamma and its lipid products. Trends Cell Biol (2000) 2.59

Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res (2007) 2.49

Pharmaceutical advertisements in medical journals. Ann Intern Med (1992) 2.49

Breast symptoms among women enrolled in a health maintenance organization: frequency, evaluation, and outcome. Ann Intern Med (1999) 2.46

Generation and assembly of secretory antibodies in plants. Science (1995) 2.45

The carriage of Escherichia coli resistant to antimicrobial agents by healthy children in Boston, in Caracas, Venezuela, and in Qin Pu, China. N Engl J Med (1990) 2.40

The heparan sulfate-fibroblast growth factor family: diversity of structure and function. Prog Nucleic Acid Res Mol Biol (1998) 2.36

Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation (1999) 2.36

alpha 5 Subunit alters desensitization, pharmacology, Ca++ permeability and Ca++ modulation of human neuronal alpha 3 nicotinic receptors. J Pharmacol Exp Ther (1998) 2.33

Relationship between the volume of total hip replacements performed by providers and the rates of postoperative complications in the state of Washington. J Bone Joint Surg Am (1997) 2.30

Clinical research in general medical journals: a 30-year perspective. N Engl J Med (1979) 2.29

Expression of the Epstein-Barr virus nuclear protein 2 in rodent cells. J Virol (1986) 2.28

A fifth Epstein-Barr virus nuclear protein (EBNA3C) is expressed in latently infected growth-transformed lymphocytes. J Virol (1988) 2.27

Factors affecting movement of F-actin filaments propelled by skeletal muscle heavy meromyosin. Am J Physiol (1992) 2.25

Improving emergency-room patient follow-up in a metropolitan teaching hospital. Effect of a follow-up check. N Engl J Med (1974) 2.23

Transcriptome analysis and molecular signature of human retinal pigment epithelium. Hum Mol Genet (2010) 2.20

Functional implications of the structure of the murine parvovirus, minute virus of mice. Structure (1998) 2.17

Delineation of the cis-acting element mediating EBNA-2 transactivation of latent infection membrane protein expression. J Virol (1991) 2.16

Effect of false-positive mammograms on interval breast cancer screening in a health maintenance organization. Ann Intern Med (1999) 2.16

The effect of waiting for radiotherapy for grade III/IV gliomas. Radiother Oncol (2000) 2.01

Low back pain hospitalization. Recent United States trends and regional variations. Spine (Phila Pa 1976) (1994) 2.00

Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem (2000) 2.00

Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst (2001) 1.95

Gating of cystic fibrosis transmembrane conductance regulator chloride channels by adenosine triphosphate hydrolysis. Quantitative analysis of a cyclic gating scheme. J Gen Physiol (1999) 1.92

Differential modulation of proliferation in the neocortical ventricular and subventricular zones. J Neurosci (2000) 1.89

US Preventive Services Task Force. Screening for breast cancer with breast self-examination. A critical review. JAMA (1987) 1.86

An animal model for acute and persistent Epstein-Barr virus infection. Science (1997) 1.85

Differential display using one-base anchored oligo-dT primers. Nucleic Acids Res (1994) 1.85

Methicillin-resistant Staphylococcus aureus from China characterized by digestion of total DNA with restriction enzymes. Epidemiol Infect (1989) 1.85

An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science (1993) 1.81

Blindness due to cataract: epidemiology and prevention. Annu Rev Public Health (1996) 1.80

Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene (2012) 1.80

The Epstein-Barr virus nuclear protein 2 acidic domain can interact with TFIIB, TAF40, and RPA70 but not with TATA-binding protein. J Virol (1995) 1.79

Identification of a CD8 T cell that can independently mediate autoimmune diabetes development in the complete absence of CD4 T cell helper functions. J Immunol (2000) 1.77

An olfactory sensory map develops in the absence of normal projection neurons or GABAergic interneurons. Neuron (1998) 1.76

Genistein potentiates wild-type and delta F508-CFTR channel activity. Am J Physiol (1997) 1.72

Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin. Mol Endocrinol (1992) 1.71

Malthusian models and Chinese realities: the Chinese demographic system, 1700-2000. Popul Dev Rev (1999) 1.69

Comparative analysis identifies conserved tumor necrosis factor receptor-associated factor 3 binding sites in the human and simian Epstein-Barr virus oncogene LMP1. J Virol (1996) 1.67

The periodic health examination: comparison of recommendations and internists' performance. South Med J (1981) 1.66

The cardiac anesthesia risk evaluation score: a clinically useful predictor of mortality and morbidity after cardiac surgery. Anesthesiology (2001) 1.66

Structure and function of neuronal nicotinic acetylcholine receptors. Prog Brain Res (1996) 1.66

Thyroid disorders in systemic lupus erythematosus. Ann Rheum Dis (1986) 1.66

Journal reading habits of internists. J Gen Intern Med (2000) 1.63

Plasma antioxidants and risk of cortical and nuclear cataract. Epidemiology (1993) 1.63

Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc Natl Acad Sci U S A (2000) 1.62

Epstein-Barr virus latent infection membrane protein increases vimentin expression in human B-cell lines. J Virol (1989) 1.60

Rings of anionic amino acids as structural determinants of ion selectivity in the acetylcholine receptor channel. Proc Biol Sci (1991) 1.59

A ring of uncharged polar amino acids as a component of channel constriction in the nicotinic acetylcholine receptor. FEBS Lett (1991) 1.53

A case-control study of risk factors for playground injuries among children in Kingston and area. Inj Prev (1998) 1.52

Formation of precise connections in the olfactory bulb occurs in the absence of odorant-evoked neuronal activity. Neuron (2000) 1.52

Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. J Biol Chem (1999) 1.50

Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus (1995) 1.50

Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol Pharmacol (1995) 1.49

Breast cancer following treatment for Hodgkin's disease: the need for screening in a young population. Australasian Radiation Oncology Lymphoma Group (AROLG) Australas Radiol (1995) 1.48

Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res (1997) 1.48

Physicians' abilities to detect lumps in silicone breast models. JAMA (1985) 1.46

Sequence and functional analysis of EBNA-LP and EBNA2 proteins from nonhuman primate lymphocryptoviruses. J Virol (2000) 1.46

Cyclin-dependent kinases as a therapeutic target for stroke. Proc Natl Acad Sci U S A (2000) 1.45

Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. Aliment Pharmacol Ther (2012) 1.45

Ah receptor agonists as endocrine disruptors: antiestrogenic activity and mechanisms. Toxicol Lett (1998) 1.44